Arrowhead Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- Arrowhead Pharmaceuticals's estimated annual revenue is currently $138.3M per year.
- Arrowhead Pharmaceuticals received $52.5M in venture funding in January 2018.
- Arrowhead Pharmaceuticals's estimated revenue per employee is $273,300
- Arrowhead Pharmaceuticals's total funding is $449.9M.
- Arrowhead Pharmaceuticals's current valuation is $6B. (January 2022)
Employee Data
- Arrowhead Pharmaceuticals has 506 Employees.
- Arrowhead Pharmaceuticals grew their employee count by 23% last year.
Arrowhead Pharmaceuticals's People
Name | Title | Email/Phone |
---|---|---|
1 | Group VP, Chemistry | Reveal Email/Phone |
2 | Group VP, Program Management | Reveal Email/Phone |
3 | Group VP, Biology | Reveal Email/Phone |
4 | Group VP, Chemistry, Manufacturing & Controls | Reveal Email/Phone |
5 | CFO | Reveal Email/Phone |
6 | Group VP, Intellectual Property & Associate General Counsel | Reveal Email/Phone |
7 | VP | Reveal Email/Phone |
8 | Chief Discovery and Translational Medicine | Reveal Email/Phone |
9 | Head Tax | Reveal Email/Phone |
10 | Head People Services & Culture | Reveal Email/Phone |
Arrowhead Pharmaceuticals Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $84.8M | 422 | 24% | N/A | N/A |
#2 | $0.4M | 2 | 0% | N/A | N/A |
#3 | $32M | 159 | 3% | N/A | N/A |
#4 | $35M | 121 | 3% | $62.5M | N/A |
#5 | $30.2M | 150 | 18% | N/A | N/A |
#6 | $135.3M | 673 | 0% | N/A | N/A |
#7 | $110.3M | 549 | N/A | N/A | N/A |
#8 | $60.1M | 299 | -4% | N/A | N/A |
#9 | $554.8M | 1725 | 2% | N/A | N/A |
#10 | $10.5M | 52 | 4% | N/A | N/A |
What Is Arrowhead Pharmaceuticals?
Arrowhead Pharmaceuticals is a clinical stage, Nasdaq listed (ticker ARWR) company developing medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, our therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Our RNAi-based therapeutics are at the leading edge of genetic-based therapy with the potential to bring life changing treatments for patients. Our Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. The TRiM platform builds on more than a decade of work on actively targeted drug delivery and offers several advantages including simplified manufacturing and reduced costs; multiple routes of administration; and potential for improved safety. Our employees are nimble, science-driven, and innovative professionals. A career at Arrowhead offers the opportunity to collaborate with top notch scientists to rapidly discover and develop RNAi-based therapeutics to add to our growing pipeline. Research and development activities are located in Madison, WI. Our R&D group includes fully-integrated capabilities for chemistry, biology, and toxicology. Madison is an exciting and sophisticated city that includes state government, the flagship campus of the University of Wisconsin, and major research organizations. Our HQ, clinical and regulatory operations are located in Pasadena, CA. Just north of Los Angeles and resting in the foothills of the San Gabriel Mountains, Pasadena is known for its natural scenic beauty, vibrant cultural and academic environment and rich architectural setting.
keywords:N/A$449.9M
Total Funding
506
Number of Employees
$138.3M
Revenue (est)
23%
Employee Growth %
$6B
Valuation
N/A
Accelerator
Arrowhead Pharmaceuticals News
Investors in Arrowhead Pharmaceuticals Inc (Symbol: ARWR) saw new options become available this week, for the December 16th expiration.
Investment Thesis. Here we tell why Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) investors need Risk/Reward ratio comparisons in 2022 far more...
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them.
Pasadena-based Arrowhead Pharmaceuticals, a biopharmaceuticals developer aiming at treating hepatitis and other diseases has raised $45M in a private offering, the company said today. The publicly held firm, which trades as ARWR on the NASDAQ, said the funding came from Orbimed, RA Capital Manag ...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | N/A | 514 | 11% | N/A |
#2 | $182.3M | 540 | 9% | N/A |
#3 | $166M | 542 | 33% | N/A |
#4 | $103.5M | 571 | 6% | N/A |
#5 | $127.3M | 617 | -3% | N/A |
Arrowhead Pharmaceuticals Funding
Date | Amount | Round | Lead Investors | Reference |
---|---|---|---|---|
2016-08-10 | $45.0M | Undisclosed | Cantor Fitzgerald & Co | Article |
2017-01-12 | $9.6M | Undisclosed | Silence Therapeutics | Article |
2018-01-19 | $52.5M | Undisclosed | Jefferies LLC | Article |